Wesbanco Bank Inc. Sells 58,967 Shares of Novo Nordisk A/S $NVO

Wesbanco Bank Inc. lessened its position in Novo Nordisk A/S (NYSE:NVO) by 77.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,553 shares of the company’s stock after selling 58,967 shares during the quarter. Wesbanco Bank Inc.’s holdings in Novo Nordisk A/S were worth $893,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the third quarter valued at $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter valued at $30,000. WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust bought a new position in Novo Nordisk A/S in the fourth quarter valued at $28,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S in the fourth quarter valued at $29,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $46.02 on Monday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average of $38.71 and a 200-day moving average of $46.97. The firm has a market cap of $205.47 billion, a P/E ratio of 10.80, a P/E/G ratio of 4.14 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Sell-side analysts expect that Novo Nordisk A/S will post 3.43 EPS for the current year.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NVO. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Citigroup began coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.